Sugi Predict

Sugi Predict / Compounds / SCHEMBL143225

SCHEMBL143225

SCHEMBL143225

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1CC(=O)N1C[C@@H](C)N[C@@H](C)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 8/20 0.59
▸ FGFR1 P11362 8/20 0.59
▸ KDR P35968 8/20 0.59
▸ SRC P12931 7/20 0.59
▸ PDGFRB P09619 6/20 0.59
▸ RET P07949 3/20 0.59
▸ FLT3 P36888 3/20 0.59
▸ MAP4K2 Q12851 3/20 0.59
▸ STK3 Q13188 3/20 0.59
▸ AURKB Q96GD4 3/20 0.59
▸ LCK P06239 3/20 0.59
▸ EGFR P00533 2/20 0.59
▸ CDK2 P24941 2/20 0.59
▸ PTK2B Q14289 2/20 0.59
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ TDP1 Q9NUW8 2/20 0.59
▸ PLK4 O00444 2/20 0.59
▸ GAK O14976 2/20 0.59
▸ JAK2 O60674 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143006 0.93 FGFR1 (0.59) METFGFR1KDRSRCPDGFRB
SCHEMBL147758 0.90 KDR (0.51) METFGFR1KDRSRCPDGFRB
SCHEMBL139643 0.89 FGFR1 (0.61) METFGFR1KDRSRCPDGFRB
SCHEMBL139972 0.89 FGFR1 (0.63) METFGFR1KDRSRCPDGFRB
SCHEMBL146268 0.88 SRC (0.60) METFGFR1KDRSRCPDGFRB
SCHEMBL6272326 0.88 KDR (0.60) METFGFR1KDRSRCPDGFRB
SCHEMBL139323 0.88 MET (0.59) METFGFR1KDRSRCPDGFRB
SCHEMBL143581 0.87 SRC (0.61) METFGFR1KDRSRCPDGFRB
SCHEMBL147924 0.87 SRC (0.67) METFGFR1KDRSRCPDGFRB
SCHEMBL144442 0.86 SRC (0.58) METFGFR1KDRSRCPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 — — US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 — — US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 — — US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 — — US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 — — US disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 — — US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 MET 310/4885FGFR1 5/4885KDR 1077/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 MET 310/4885FGFR1 5/4885KDR 1077/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 MET 151/4885FGFR1 637/4885KDR 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.